NCT06412601

Happy Bob App: A Preliminary Evaluation of Its Use in Youth With Diabetes

Children's Mercy Hospital Kansas City·ClinicalTrials.gov·behavioralNot yet recruiting
View on ClinicalTrials.gov
Study focus
Disease/Condition
Type 1 Diabetes
Drug/Device/Intervention
RPM
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
Children's Mercy Hospital Kansas City
Timeline & enrollment
Phase
N/A
Start date
Jul 01, 2024
End date
Dec 31, 2024
Enrollment
80 participants
Primary outcome

Happy Bob App User Metrics,Type 1 Diabetes and Life (T1DAL) Measure,Positive and Negative Affect Schedule (PANAS),Diabetes Treatment Satisfaction Questionnaire,Social Support Questionnaire for Children (SSQC),Health Information Technology Usability Evaluation Scale (Health-ITUES)

Summary

The goal of this clinical trial is to evaluate the impact of peer support via the Happy Bob
 phone app in youth with Type 1 Diabetes.
 
 The main questions it aims to answer are: What is the usability and acceptability of the app?
 What is the app's efficacy on measures such as treatment adherence and social support? And
 how are these effects impacted by remote patient monitoring by clinic staff?
 
 Participants will use the Happy Bob app for 6 months and will complete a series of surveys at
 the start, middle, and end of their use of the app. Some participants will participate in 2
 remote patient monitoring sessions when beginning their use of the app.

ICD-10 classifications
Type 1 diabetes mellitusType 1 diabetes mellitus without complicationsType 1 diabetes mellitus with unspecified complicationsType 1 diabetes mellitus with other specified complicationsType 1 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06412601
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06412601 through Pure Global AI's free database. This phase not specified trial is sponsored by Children's Mercy Hospital Kansas City and is currently Not yet recruiting. The study focuses on Type 1 Diabetes. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.